IntelliPharmaCeutics International Inc. IPCI was a big mover last session, as the company saw its shares climb above 5% on the day. The upside came after the company inked an exclusive license and commercial supply agreement with Mallinckrodt Pharmaceuticals (MNK). This continues the recent uptrend of the company, as the stock is now up 68.36% in the past one-month time frame.
The company has seen no estimate revision in the past one month and its Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
IntelliPharmaCeutics currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.
A better-ranked stock in the healthcare sector is Ariad Pharmaceuticals Inc. ARIA, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research